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An exciting recent study examining the methylation
profile of human brain tissue implicates early-life
epigenetic disruption in the neurodevelopmental
origin of schizophrenia.[2] identify distinct methylomic profiles in the prefrontalSchizophrenia is a debilitating neuropsychiatric disorder,
with a lifetime prevalence of close to 1%, characterized
by frequent psychotic episodes. There is a strong heredi-
tary component that, until recently, remained largely unex-
plained, hampered by the involvement of a large number
of gene variants with small effects, as well as rarer genes
and copy-number variants with substantial effects. The
largest and most recent genome-wide association study
(GWAS) of 35,000 schizophrenia cases, and three times as
many controls, has identified 83 novel loci contributing to
overall risk, as well as 25 genes that had previously been
implicated in the disease [1].
Although the peak onset of schizophrenia is in the
adolescent and early-adult years, many believe this to be
a disorder of neurodevelopment, with etiological origins
much earlier in life. Indeed, it is thought that abnormal-
ities occurring during the very early stages of development,
caused by both environmental and genetic factors, trigger
a cascade of processes cumulating in the emergence of
symptoms at a later age. This neurodevelopmental hypoth-
esis is supported by the findings of epidemiological studies
linking early-life stress exposures with later risk of disease,
as well as genetic association studies indicating the in-
volvement of key genes in brain development. However,
no study has yet provided insights into the possible* Correspondence: richard.saffery@mcri.edu.au
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Epigenetic variation is known to be susceptible to the envir-
onment, and insults occurring during neurodevelopment
could conceivably leave a lasting impact on the epigenome
and later phenotype.
In this issue of Genome Biology, Pidsley and colleagues
cortex (PFC) of the adult schizophrenic brain, which are
replicated in an independent sample. Furthermore, by
comparison with early-life human fetal brain samples, the
authors demonstrate that several schizophrenia-associated
differentially methylated probes map to genes with roles
in fetal brain development. These findings thus provide
compelling support for the neurodevelopmental hypoth-
esis of schizophrenia and suggest, for the first time, a
role for early-life epigenetic disruption in mediating these
effects [2].
Epigenetic analysis: peripheral biomarkers versus
central nervous system disease-associated
variation
Given the likely involvement of both genetic and environ-
mental components to disease risk, increasing research has
focused on the role of epigenetics in the pathophysiology of
schizophrenia. As with many complex disorders, recent
work has taken a ‘hypothesis-free’ epigenome-wide ap-
proach to the study of DNA methylation. Broadly speaking,
these studies fall into two categories: those investigating
methylation in peripheral tissue of living individuals and
those examining DNA methylation in post mortem cen-
tral nervous system (CNS) tissue.
A comparison of leukocyte DNA methylation between
24 medication-naive schizophrenia cases and 23 controls
using the Illumina Infinium HumanMethylation450 array
platform identified 234 disease-associated genomic sites of
differential methylation [3]. These were subsequently rep-
licated in a cohort of three monozygotic twin pairs dis-
cordant for the disorder. A more recent study combined
affinity purification of methylated DNA and deeptral Ltd. The licensee has exclusive rights to distribute this article, in any
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738 controls [4]. A number of significant sites of differen-
tial methylation were identified, including FAM63B, impli-
cated in neuronal differentiation, and RELN (encoding the
serine protease reelin), the most widely studied candidate
gene in methylation studies. Importantly, replication
of key findings was carried out in an independent case–
control sample.
Although blood-based studies can reveal biomarkers
of schizophrenia, their relevance to disease etiology is
questionable, given the tissue-specific nature of epigenetic
profiles. Thus, studies of post mortem CNS tissue, such as
that undertaken by Pidsley and colleagues [2], are very im-
portant from an etiological perspective. A number have
been previously reported, although replication of individ-
ual findings is unfortunately limited, most likely owing to
small sample sizes, different study populations and incon-
sistent methodological approaches.
The first foray into the area was reported in 2008, using
post mortem brain tissue of 35 individuals with schizo-
phrenia and 28 matched controls [5]. Data were generated
for 12,192 CpG islands by hybridization to the unmethy-
lated fraction of genomic DNA. Considerable evidence for
epigenetic changes in association with schizophrenia was
reported, with a number of loci involved in neuronal de-
velopment, in addition to glutamatergic and GABAergic
genes.
More recent studies have carried out epigenome-wide
association studies (EWAS) using the robust Illumina
Infinium HumanMethylation BeadChip platform. The
first-generation 27K arrays were used to profile DNA
methylation in 216 PFC samples, including 97 schizo-
phrenia cases, in conjunction with genome-wide single-
nucleotide polymorphism (SNP) analysis. A total of 107
disease-associated sites of differential methylation were
found, the majority of which showed increasing methyla-
tion in disease. Interestingly, a number of cis-methylation
quantitative trait loci (QTLs - SNPs associated with DNA
methylation levels at specific genomic sites) were also
identified, including at SNPs previously associated with
schizophrenia [6]. For example, the A allele of rs6311, pre-
viously linked to schizophrenia, was associated with higher
methylation at the serotonin receptor (HTR2A) gene en-
coding 5-hydroxytryptamine receptor 2A.
The next-generation Infinium HumanMethylation450
BeadChip platform has recently been used by Wockner
and colleagues [7] to profile DNA methylation at over
485,000 sites in post mortem frontal cortex tissue from
24 schizophrenia patients and 24 controls. A total of 4,641
schizophrenia-associated differentially methylated probes
were identified after adjusting for age and post mor-
tem interval. Nearly half were hypomethylated in the
schizophrenia group, representing 2,929 unique genes
[7]. Interestingly, approximately 17% of these matched aprevious list of differentially methylated genes reported in
peripheral blood of schizophrenia subjects [8].
The Pidsley study
Cross-sectional EWAS studies, although highly inform-
ative, provide only limited information regarding schizo-
phrenia etiology and cannot rule out reverse causation as
a source of the observed differential methylation. Indeed,
it is likely that many reported methylation changes in the
brain of schizophrenia subjects result from the disease
process itself, or associated factors such as medication use.
This is where the current work of Pidsley and colleagues
stands alone. In addition to performing an EWAS for
schizophrenia per se, they have explored the ontogeny of
methylation loci of interest in the early fetal brain in order
to gauge the likelihood of disease-associated methylation
variation that has origins in early life.
Using the Infinium HumanMethylation450 BeadChip
platform, they first compared more than 485,000 CpG
sites across the genome in brain tissue from the PFC
and cerebellum of 20 schizophrenia patients and 23 age-
and gender-matched controls. Importantly, cell hetero-
geneity was considered during the analysis. A number of
PFC-specific sites of differential methylation were found
between patients and controls, with four gene-associated
probes reaching genome-wide significance levels. The gene
GSDMD (encoding gasdermin-D) showed, on average, 4.4%
increased methylation in patients, whereas the GTPase-
activating protein gene RASA3, PPFIA1 (encoding liprin-
alpha-1) and HTR5A had decreased methylation in
patients compared with controls (effect sizes ranging from
a mean of 2.3% to 8.7%).
Using an alternative approach of data aggregation across
adjacent probes, regions of coordinated differential methy-
lation were also identified, including an 8-kb block of 28
hypomethylated probes (average decrease of 1.8% between
cases and controls) within the NRN1 gene body (encoding
neuritin). Genetic variation in NRN1 has previously been
associated with schizophrenia [9], and it is known to play
a crucial role in neurodevelopment and synaptic plasticity.
Importantly, all of the significant differences were specific
to the PFC, a brain region known to be functionally im-
portant in the etiology of schizophrenia.
The authors validated their findings by using bisulfite se-
quencing of three differentially methylated regions near
genes NRN1, C8A and RASA3 and also performed a repli-
cation analysis by using PFC samples from a second brain-
bank sample consisting of 18 schizophrenic patients and
15 controls. They found surprisingly strong correlations
between differentially methylated sites in the two cohorts
(r =0.54) and, importantly, were able to replicate the sig-
nificant hits from their initial discovery set. Weighted gene
co-methylation network analysis was employed, and 12
modules in the PFC were significantly associated with
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negative associations with the disease, which were con-
served across the two cohorts, and again were absent from
the cerebellum. Consistent findings from both pathway
and gene ontology analysis indicated that the modules
were enriched for functions involved in the development
and function of the nervous system.
Breaking new ground, Pidsley et al. then sought to de-
termine whether the differentially methylated CpG sites
associated with schizophrenia were susceptible to dynamic
methylation changes during brain development. To per-
form this analysis, they used a sample of 179 human fetal
cortex samples, aged between 23 days and 6 months post-
conception. Remarkably, the authors found that 44% of
the previously identified schizophrenia-associated sites of
differential methylation were dynamic in the brain across
pregnancy, thus providing strong new evidence in support
of a neurodevelopmental origin for schizophrenia that
is associated with early-life epigenetic disruption in the
developing brain. For example, one of the top-ranked
schizophrenia-associated differentially methylated probes,
in the gene body of MYT1L, is significantly hypomethy-
lated in cases relative to controls and is also highly
dynamic in association with neocortical development.
MYT1L encodes a potent myelin transcription-factor-
like protein integral to neurodevelopment.
Replication, replication, replication
A limitation of the Pidsley study is that only limited com-
parisons with previous data were made. A goal for the fu-
ture should be the use of a single methylation platform by
multiple teams to examine post mortem brain biopsies,
which will facilitate a direct comparison of findings across
different studies. Nonetheless, several of the genes show-
ing differential methylation in this study have also recently
been linked to schizophrenia as part of a large inter-
national GWAS initiative [1], including calcium channel
subunit CACNA1C, the t-SNARE domain-containing pro-
tein TSNARE1, the phosphatidylinositol transfer protein
PITPNM2 and the leukocyte antigen HLA-L. Perhaps just
as important as the reported findings is what can be found
buried within supplementary data that highlights common
‘hits’ in at least two, if not more, instances. For example,
the kinesin light chain-1 gene KLC1 shows altered DNA
methylation in Pidsley et al. [2] and Wockner et al. [7]
and is also located within one of the 108 genomic loci as-
sociated with schizophrenia by GWAS. The MYT1L gene
is also differentially methylated in both epigenetic studies.
Furthermore, whereas direct replication across studies
is not apparent for many genes, consistent classes of
gene families are reported across multiple genetic and
epigenetic analyses. This includes multiple calcium chan-
nel and serotonin transporter genes. Numerous other
overlaps exist, although it is important to point out thatthe majority of ‘hits’ in any one study are not present in
any other.
Concluding remarks
This study presents a novel approach to tackling one of
the most problematic areas of epigenetic analysis of human
disease, namely how to determine the role of early-life epi-
genetic disruption in neuropsychiatric illness. The evidence
reported by Pidsley and colleagues supports a role for epi-
genetic variation during neurodevelopment as a contribu-
tor to schizophrenia - but remains indirect - despite being
robust across two independent cohorts. Nevertheless, data
continue to mount from other studies in support of the
underlying hypothesis, with emerging evidence implicating
disruption of multiple cellular pathways in disease etiology.
Technology in this field is rapidly advancing, and there are
many international repositories of post mortem brain ma-
terial yet to be examined. As such, we can expect to see
many more studies using higher-density methylation pro-
filing in the near future. However, the now-conclusive role
of underlying genetic variation in determining the methyla-
tion status of many genomic loci necessitates future studies
combining both genetic and DNA methylation data into a
single analysis approach. Finally, although exploring DNA
methylation is a logical first step, such studies should also
be expanded to include other epigenetic mechanisms, in-
cluding non-coding RNAs and chromatin modifications.
In summary, mounting epigenetic data appear to be
converging on common pathways and processes in the eti-
ology of schizophrenia, at least some of which are likely to
be disrupted during early development. Although individ-
ual studies are beginning to yield compelling findings, the
data are as yet inconclusive. International coordin-
ation of tissue sample availability and EWAS analysis,
in a manner similar to that which has proven so success-
ful for GWAS studies, represents the most promising
approach towards understanding the role of epigenetic
disruption in schizophrenia and other neuropsychiatric
disorders. Such efforts are already beginning to yield excit-
ing results in Alzheimer’s disease [10].Abbreviations
EWAS: Epigenome-wide association study; GWAS: Genome-wide association
study; PFC: Prefrontal cortex; QTL: Quantitative trait locus; SNP: Single-nucleotide
polymorphism.Competing interests
The authors declare they have no competing interests.Acknowledgements
The authors are supported by the National Health and Medical Research
Council, through a Senior Research Fellowship (APP1045161 to RS) and an
Early Career Researcher Fellowship (APP1012735 to JR). The Murdoch
Childrens Research Institute is supported by the Victorian Government’s
Operational Infrastructure Support Program.
Ryan and Saffery Genome Biology 2014, 15:495 Page 4 of 4
http://genomebiology.com/2014/15/10/495Author details
1Cancer and Disease Epigenetics, Murdoch Children’s Research Institute,
Royal Children’s Hospital, University of Melbourne, Parkville, VIC 3052,
Australia. 2Department of Paediatrics, University of Melbourne, Parkville, VIC
3052, Australia. 3Inserm U1061, Hopital La Colombiere and Universite
Montpellier 1, Montpellier F-34093, France.
References
1. Schizophrenia Working Group of the Psychiatric Genomics Consortium:
Biological insights from 108 schizophrenia-associated genetic loci.
Nature 2014, 511:421–427.
2. Pidsley R, Viana J, Hannon E, Spiers H, Troakes C, Al-Saraj S, Mechawar N,
Turecki G, Schalkwyk L, Bray N, Mill J: Methylomic profiling of human
brain tissue supports a neurodevelopmental origin for schizophrenia.
Genome Biol 2014, 15:483.
3. Kinoshita M, Numata S, Tajima A, Shimodera S, Ono S, Imamura A, Iga J,
Watanabe S, Kikuchi K, Kubo H, Nakataki M, Sumitani S, Imoto I, Okazaki Y,
Ohmori T: DNA methylation signatures of peripheral leukocytes in
schizophrenia. Neuromol Med 2013, 15:95–101.
4. Aberg KA, McClay JL, Nerella S, Clark S, Kumar G, Chen W, Khachane AN,
Xie L, Hudson A, Gao G, Harada A, Hultman CM, Sullivan PF, Magnusson PK,
van den Oord EJ: Methylome-wide association study of schizophrenia:
identifying blood biomarker signatures of environmental insults.
JAMA Psychiatry 2014, 71:255–264.
5. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, Jia P,
Assadzadeh A, Flanagan J, Schumacher A, Wang SC, Petronis A: Epigenomic
profiling reveals DNA-methylation changes associated with major psychosis.
Am J Hum Genet 2008, 82:696–711.
6. Numata S, Ye T, Herman M, Lipska BK: DNA methylation changes in the
postmortem dorsolateral prefrontal cortex of patients with schizophrenia.
Front Genet 2014, 5:280.
7. Wockner LF, Noble EP, Lawford BR, Young RM, Morris CP, Whitehall VL,
Voisey J: Genome-wide DNA methylation analysis of human brain tissue
from schizophrenia patients. Transl Psychiatry 2014, 4:e339.
8. Nishioka M, Bundo M, Koike S, Takizawa R, Kakiuchi C, Araki T, Kasai K,
Iwamoto K: Comprehensive DNA methylation analysis of peripheral
blood cells derived from patients with first-episode schizophrenia.
J Hum Genet 2013, 58:91–97.
9. Chandler D, Dragovic M, Cooper M, Badcock JC, Mullin BH, Faulkner D,
Wilson SG, Hallmayer J, Howell S, Rock D, Palmer LJ, Kalaydjieva L, Jablensky
A: Impact of Neuritin 1 (NRN1) polymorphisms on fluid intelligence in
schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:428–437.
10. Lunnon K, Smith R, Hannon E, De Jager PL, Srivastava G, Volta M, Troakes C,
Al-Sarraj S, Burrage J, Macdonald R, Condliffe D, Harries LW, Katsel P,
Haroutunian V, Kaminsky Z, Joachim C, Powell J, Lovestone S, Bennett
DA, Schalkwyk LC, Mill J: Methylomic profiling implicates cortical
deregulation of ANK1 in Alzheimer's disease. Nat Neurosci 2014,
17:1664–1670.
doi:10.1186/s13059-014-0495-y
Cite this article as: Ryan and Saffery: Crucial timing in schizophrenia:
role of DNA methylation in early neurodevelopment. Genome Biology
2014 15:495.
